Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04130516
Title Phase 1 Study to Determine the MTD, Safety, Tolerability, PK and Preliminary Anti-tumor Effects of LNS8801alone and in Combination With Pembrolizumab
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Linnaeus Therapeutics, Inc.
Indications

Advanced Solid Tumor

lymphoma

Therapies

LNS8801

LNS8801 + Pembrolizumab

Age Groups: senior | adult
Covered Countries USA


No variant requirements are available.